Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05253833 · ClinicalTrials.gov registry record · Phase 2
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
A Phase 2 study, sponsored by Arthrosi Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT05253833 is a Phase 2 study that has completed, run by Arthrosi Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT05253833, a Phase 2 study, has completed, sponsored by Arthrosi Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.
Interventions
- DRUG AR882 Dose 1
- DRUG AR882 Dose 2
- DRUG Allopurinol Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2024-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05253833
The ClinicalTrials.gov registry entry for NCT05253833 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arthrosi Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AR882 Dose 1 is the first listed.
NCT05253833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05253833 about?
NCT05253833 is a clinical study titled "Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout". This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.
What is the current status of trial NCT05253833?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2022-08-12. Estimated completion is 2024-10-28.
What interventions are being tested in trial NCT05253833?
The interventions under investigation include: AR882 Dose 1 (DRUG), AR882 Dose 2 (DRUG), Allopurinol Tablet (DRUG).
Who is sponsoring clinical trial NCT05253833?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.